GLP-1 drugs (glucagon-like peptide-receptor agonists) are FDA-approved drugs that mimic a natural gut hormone to regulate blood sugar, slow digestion, and increase fullness. These properties are making them highly effective for treating Type 2 diabetes and obesity. These drugs are administered via weekly or daily injections or oral tablets.
Key Usage Examples and Benefits
- Type 2 Diabetes Management: Stimulates insulin release when blood sugar is high and reduces glucagon secretion.
- Weight Loss/Management: Approved for chronic weight management in adults with a Body Mass Index(BMI) of 30 or higher (or 27+ with weight-related conditions)
How GLP-1 Drugs Benefit the Heart
These drugs were originally developed for diabetes, but large clinical trials have shown clear cardiovascular benefits:
1 Reduce Major Cardiac Events: They lower the risk of
- Heart attack &myocardial infarction)
- Stroke
- Cardiovascular death
These are especially proven in people with
- Type 2 diabetes
- Existing heart disease (like coronary artery disease)
2 Help with Weight Loss
- Significant weight loss reduces strain on the heart.
- Improves blood pressure and Cholesterol.
This indirectly lowers the risk of heart failure and ischemic heart disease.
3 Improve Blood Sugar Control
- Prevents damage to blood vessels.
- Reduces long-term cardiac complications.
4 Lowe Blood pressure & Inflammation
- Mild reduction in Blood pressure
- Anti-inflammatory effects on blood vessels.
Limitations
- Can not be used for emergency heart treatment
- Not a replacement for statins, BP medicines and antiplatelets.
- Side effects are nausea and vomiting.
These medicines are known to have side effects and should be used under medical supervision.
Availability of GLP-1 Drugs in India
They are currently available in India through a mix of innovator brands and a recent surge of affordable generic versions following a major patent expiry in March 2026. These medications are strictly prescription-based, and must be prescribed by endocrinologists or internal medicine specialists.
Innovator Brands (High Cost):
- Wegovy & Ozempic (Semaglutide): Monthly cost ranges from Rs 7,500 to 16,000.
- Mounjaro/yurpeak (Tirzepatide): Marketed by Eli Lilly ( and partner Cipla). Monthly cost ranges from Rs 10,000 to 22,000.
- Rybelsus ( Oral Semaglutide): The only widely available oral option, priced between Rs 3,000-3,600)
New Indian Generics (Lower Cost):
Following the Semaglutide patent expiry on March 20, 2026, prices for some variants have dropped by 70-90%.
- Glenmark (GLIPIQ): Monthly cost Rs 1,300 to 1,760
- Eris & Natco (Sundae): Monthly cost starts from Rs 1,290.
- Sun Pharma (Noveltreat/Sematrinity)- starts att Rs 750 to Rs 2000.
- Alkem (Semasize/Obesama) – priced around Rs 1,800.
- Dr Reddy’s (Obeda) is priced at Rs 4,200 per month.
- Zydus (Smaglyn/mashema) is priced around Rs 2,200 per month.
In the end, GLP-1 drugs are a breakthrough in the treatment of diabetes, obesity and to some extent help in the prevention of heart disease.
Anil Malik
Mumbai, India
25th March 2026